Lys135

Site Information
RRELAKMkQEPVRSE SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 12093967

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 3 , 4 , 5 , 6 )
Relevant cell line - cell type - tissue:	HeLa (cervical) ( 4 ) , HEp-2 (squamous) ( 1 ) , Jurkat (T lymphocyte) ( 1 ) , LNCaP (prostate cell) ( 6 ) , PC3 (prostate cell) ( 5 ) , U2OS (bone cell) ( 3 )

References
1	Akimov V, et al. (2018) UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol 25, 631-640 29967540 Curated Info
2	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
3	Povlsen LK, et al. (2012) Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypass. Nat Cell Biol 14, 1089-98 23000965 Curated Info
4	Moritz A (2010) CST Curation Set: 9062; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
5	Possemato A (2009) CST Curation Set: 8584; Year: 2010; Biosample/Treatment: cell line, PC3/Geldanamycin; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
6	Possemato A (2009) CST Curation Set: 8246; Year: 2010; Biosample/Treatment: cell line, LNCaP/Velcade; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info